Harbour Investments Inc. Buys 20,136 Shares of Pfizer Inc. $PFE

Harbour Investments Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 25.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,829 shares of the biopharmaceutical company’s stock after purchasing an additional 20,136 shares during the quarter. Harbour Investments Inc.’s holdings in Pfizer were worth $2,436,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. Horizon Financial Services LLC increased its stake in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the last quarter. YANKCOM Partnership purchased a new stake in Pfizer in the 4th quarter valued at about $28,000. HFM Investment Advisors LLC increased its stake in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the last quarter. Darwin Wealth Management LLC purchased a new stake in Pfizer in the 2nd quarter valued at about $32,000. Finally, Torren Management LLC purchased a new stake in Pfizer in the 4th quarter valued at about $34,000. Institutional investors own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced new late-stage trial activity for its infant pneumococcal vaccine and obesity drug berobenatide, reinforcing that the company is pushing to build future growth drivers beyond its aging portfolio. Pfizer’s Next-Gen Infant Pneumococcal Vaccine Trial: What Investors Should Watch Now
• Positive Sentiment: BofA Securities raised its price target on Pfizer to $27 from $26 after strong first-quarter results and improved 2026 revenue/EPS estimates, signaling continued analyst confidence in the stock’s valuation. BofA Raises Price Target on Pfizer (PFE) Following Strong Q1 Results
• Positive Sentiment: Pfizer is also highlighting its obesity push with a new Phase 3 trial, which could add another major opportunity if results are favorable. Pfizer Steps Up Obesity Push With New Phase 3 Berobenatide Trial
• Neutral Sentiment: Recent commentary says Pfizer is leaning on new launches, Seagen assets, and pipeline progress to offset looming loss-of-exclusivity pressure, but the patent cliff through 2030 remains a major overhang for investors. Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure?
• Negative Sentiment: Broader industry coverage on the Eliquis patent cliff underscores the kind of revenue loss Pfizer and peers can face when exclusivity ends, keeping attention on the company’s future replacement pipeline. Thinning revenues: inside the $14bn Eliquis patent cliff

Pfizer Stock Up 1.5%

PFE opened at $26.24 on Thursday. The company has a 50 day moving average of $26.82 and a 200 day moving average of $26.27. The company has a market cap of $149.55 billion, a PE ratio of 20.03 and a beta of 0.35. Pfizer Inc. has a 12 month low of $23.06 and a 12 month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. Barclays initiated coverage on shares of Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research note on Thursday, February 12th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Guggenheim increased their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Bank of America decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.61.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.